Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success for developing this treatment, and some study results to date (Abstract PL03.05).
Dean Fennell, FRCP, PhD, of the University of Leicester, discusses phase III results from the CONFIRM trial, which sought a standard immunotherapy treatment to improve overall survival for patients with mesothelioma who have relapsed after taking pemetrexed and cisplatin. Globally, the incidence of ...
Thierry André, MD, of Hôpital Saint-Antoine, discusses results from the GARNET study, which showed that dostarlimab, an anti–PD-1 antibody, demonstrated durable antitumor activity in patients with mismatch repair–deficient colorectal and noncolorectal solid tumors. No new safety signals were...
Richard S. Finn, MD, of the UCLA Medical Center, discusses updated results from the IMbrave 150 study, which showed atezolizumab plus bevacizumab provides the longest overall survival seen in a front-line phase III study in advanced hepatocellular carcinoma, confirming this combination as the...
Kai-Keen Shiu, MD, PhD, of the University College Hospital NHS Foundation Trust - London, discusses an interim analysis of PFS 2 results (defined as time from random assignment to progression on the next line of therapy or death) from the phase III KEYNOTE-177 trial. This study has already shown...
Wasat Mansoor, MBChB, PhD, of The Christie NHS Foundation Trust, discusses phase III results from the KEYNOTE-590 trial, which showed no deterioration in health-related quality of life when pembrolizumab was added to chemotherapy in patients with metastatic and unresectable esophageal cancers...
Zev A. Wainberg, MD, of UCLA Medical Center, discusses phase II results from the FIGHT study, which combined bemarituzumab with modified FOLFOX6 in first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma. This is reportedly the first randomized trial of any FGFR inhibitor, ...
Joyce V. Lee, PhD, of the University of California, San Francisco, discusses data that suggest the MYC oncogene may indicate whether a patient with triple-negative breast cancer will respond to immunotherapy. Dr. Lee’s study is the first to describe MYC downregulation of MHC-I and to demonstrate...
Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, reviews six important abstracts on CAR T-cell treatments for B-cell acute lymphoblastic leukemia (ALL): successful 24-hour manufacture of CAR T-cell therapy; ALLCAR19, a novel fast-off rate therapy; donor-derived CD19-targeted...
Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs chemotherapy in patients with previously treated metastatic triple-negative breast cancer (Abstract GS3-06).
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, offers his expert views on five treatment studies in mantle cell lymphoma focusing on the next-generation BTK inhibitor LOXO-305; lisocabtagene maraleucel; minimal residual disease monitoring following autologous stem cell...
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses phase II results from a single-center study that explored a novel approach for high-risk patients with mantle cell lymphoma. Among patients with TP53 wild-type disease, the data suggested this treatment was effective...
Meletios A. Dimopoulos, MD, of the University of Athens, discusses data from the phase III APOLLO study, which evaluated the use of subcutaneous daratumumab plus pomalidomide and dexamethasone, vs pomalidomide and dexamethasone alone, in patients with relapsed or refractory multiple myeloma...
Caron A. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses results from the ZUMA-9 C2 study, an ongoing trial that is exploring axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma (Abstract 2100).
Sagar Lonial, MD, of the Emory University School of Medicine, summarizes key papers presented in a session he co-moderated on how second-generation CAR T cells can be used to treat patients with multiple myeloma (Session 653).
Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-year recurrence-free and overall survival results from the CheckMate 238 study, which showed adjuvant nivolumab continues to be an effective treatment, vs the comparator ipilimumab, for patients with resected...
Lisa A. Carey, MD, of the University of North Carolina, discusses phase III results from two IMpassion trials, 130 and 131, which explored, respectively, atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast...
Alexander M. Eggermont, MD, PhD, of the Princess Maxima Center for Pediatric Oncology, discusses final results of the phase III EORTC 1325-MG/Keynote 054 trial, which confirmed a sustained recurrence-free survival benefit of pembrolizumab vs placebo in patients with resected high-risk stage III...
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses results from the phase III ASCENT trial, which showed the antibody-drug conjugate sacituzumab govitecan-hziy improved progression-free and overall survival more than standard single-agent chemotherapy in patients...
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses results of the phase II PRINCEPS trial, which assessed, for the first time, the effect of just one injection of the immunotherapy atezolizumab before surgery in patients with resectable non–small cell lung cancer (Abstract...
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori, discusses phase II results on progression-free survival for patients with advanced melanoma in the SECOMBIT study, whose aim is to evaluate the different sequencing of a BRAF inhibitor (encorafenib) plus a MEK inhibitor (binimetinib) with...
Thierry Andre, MD, of Hôpital Saint-Antoine, discusses phase III KEYNOTE-177 findings on the reduced risk of disease progression or death in patients receiving pembrolizumab monotherapy as a first-line treatment of microsatellite instability–high and/or mismatch repair–deficient metastatic...
Sumanta K. Pal, MD, of the City of Hope National Medical Center, discusses results from the COSMIC-021 study, which tested two different doses of cabozantinib, each with a standard dose of atezolizumab, administered to patients with metastatic advanced clear cell renal cell carcinoma. Dr. Pal...
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses primary results of the phase III JAVELIN trial of locally advanced squamous cell carcinoma of the head and neck, in which the immune checkpoint inhibitor avelumab was combined with chemoradiotherapy followed by avelumab...
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the first results from the phase III CheckMate 9ER trial, which suggested the combination of nivolumab and cabozantinib is safe. It showed activity in progression-free and overall survival, as well as in overall response rates and may ...
Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses results of the CheckMate 743 trial, which suggests nivolumab plus ipilimumab should be considered the new standard of care in first-line treatment of unresectable malignant pleural mesothelioma, regardless of the histology subtype...
Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunotherapy or activates immunotherapy. He also discussed how to improve the interaction of these treatments, perhaps with...
Silvia Formenti, MD, of Weill Cornell Medical College, discusses her continuing work, and the promising results emerging, in combining radiotherapy with immunotherapy to boost abscopal response rates. This combination therapy extends the use of radiotherapy to promote antitumor T-cell responses for ...
In this video, Drs. Ramalingam, Brahmer, and Wakelee discuss the latest in emerging data on chemo/immunotherapy and immunotherapy-based combination approaches for the treatment of non–small cell lung cancer. They review recent data presented during the ASCO20 Virtual Scientific Program, including...
Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint blockade (ICB) is safe and causes no surgical delays in early-stage lung cancer, and that major pathologic response rates are...
Efstathios Kastritis, MD, of the University of Athens, discusses phase III findings of the Andromeda study. Adding daratumumab to cyclophosphamide, bortezomib, and dexamethasone resulted in deeper and more rapid hematologic responses and improved clinical outcomes in patients with newly diagnosed...
Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphamide, vincristine, and prednisolone is a feasible and effective regimen for front-line treatment of high-risk patients with...
Sarah A. Holstein, MD, PhD, of the University of Nebraska Medical Center, discusses top myeloma abstracts from the ASCO20 Virtual Scientific Program: the ENDURANCE trial on carfilzomib, lenalidomide, dexamethasone, and bortezomib; the STaMINA study on transplantation strategies; a first-in-human...
Michael J. Dickinson, MBBS, DMedSc, of the Peter MacCallum Cancer Centre, discusses phase I dose-escalation study results on CD20-TCB, which showed activity, including durable complete responses, and manageable safety in heavily pretreated patients with relapsed or refractory non-Hodgkin lymphoma...
Parameswaran Hari, MD, of the Medical College of Wisconsin, discusses data from four trials and their clinical implications for the treatment of patients with multiple myeloma: the KarMMa and EVOLVE studies on CAR T cell therapies; SWOG-1211 on bortezomib, lenalidomide, and dexamthasone...
Nikhil C. Munshi, MD, of Dana-Farber Cancer Institute, discusses initial results from the KarMMa tria, showing that idecabtagene vicleucel, a B-cell maturation antigen-targeted CAR T-cell therapy, demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory...
Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses interim results from the DESTINY-Lung01 trial of fam-trastuzumab deruxtecan in patients with HER2-mutated metastatic non–small cell lung cancer. The data show clinical activity with high overall response rates and durable...
Lakshmi Nayak, MD, of Dana-Farber Cancer Institute, reviews two key abstracts on newly diagnosed primary central nervous system lymphoma and treatment with whole-brain radiotherapy, methotrexate, temozolomide, rituximab, procarbazine, vincristine, and cytarabine (Abstracts 2500 and 2501).
Suresh S. Ramalingam, MD, of Emory University, discusses a 3-year update from the CheckMate 227, Part 1, trial, which showed that nivolumab plus ipilimumab continued to provide durable and long-term overall survival benefit vs platinum-doublet chemotherapy as first-line treatment for patients with...
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve only a PET/CT-positive partial remission, is appropriate in the era of CAR T-cell therapy (Abstract 8000).
Rachel E. Sanborn, MD, of the Providence Cancer Institute, discusses three key abstracts on EGFR-mutated non–small cell lung cancer: a final overall survival analysis of bevacizumab plus erlotinib; concurrent osimertinib plus gefitinib for first-line treatment; and first-line treatment with a...
Douglas B. Johnson, MD, of Vanderbilt University Medical Center, discusses three important melanoma abstracts: the need for more than two doses of nivolumab plus ipilimumab in combination immunotherapy; antitumor activity for low-dose ipilimumab with pembrolizumab after disease progression on PD-1...
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).
Thierry André, MD, of Hôpital Saint-Antoine, discusses the phase III results from KEYNOTE-177, which showed that, compared with standard chemotherapy of FOLFOX or FOLFIRI, pembrolizumab doubled median progression-free survival, from 8.2 months to 16.5 months, in patients with microsatellite...
Richard L. Schilsky, MD, Chief Medical Officer of ASCO, talks about some of the most important and practice-changing findings presented this year at the ASCO20 Virtual Scientific Program, including the use of targeted and immunotherapies in earlier lines of therapy, where they have made a...
Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results of the BEACON CRC study, which confirmed that, compared with standard chemotherapy, encorafenib plus cetuximab with or without binimetinib improved overall survival and objective response rate...
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, talks with Thomas Powles, MD, PhD, of Queen Mary University of London, about the first study to demonstrate a survival advantage with avelumab for metastatic urothelial cancer. In the trial, avelumab improved median overall survival by...
As Thomas Powles, MD, PhD, of Queen Mary University of London, prepares to deliver his late-breaking presentation at the ASCO20 Virtual Scientific Program (LBA-1), he talks with Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, about current therapy: PD1/PDL1 inhibition in second-line...
Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer who had a past medical history of pneumonitis were more likely to experience treatment-associated pneumonitis in response to immune checkpoint inhibitors or...
Edward B. Garon, MD, of the University of California, Los Angeles David Geffen School of Medicine, discusses KEYNOTE-189 trial findings that showed adding pembrolizumab to pemetrexed plus platinum—which previously was found to improve overall and progression-free survival—is also safe and has...